epcoritamab
Sponsor Genmab A/S · listed as GMAB
epcoritamab is a drug asset sponsored by Genmab A/S, listed as GMAB. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2027 (month precision, medium confidence), tied to trial NCT05578976. That trial is in Phase 3 and currently active not recruiting, studying Diffuse Large B-Cell Lymphoma. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for epcoritamab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04628494 | Phase 3 | Active, not recruiting | 2025-10-13 | Experimental | Genmab | Diffuse Large B-cell Lymphoma |
| NCT07226752 | Phase 3 | Active, not recruiting | 2025-10-13 | Experimental | Genmab | Diffuse Large B-Cell Lymphoma |
| NCT05578976 catalyst | Phase 3 | Active, not recruiting | 2027-06 | Experimental | Genmab | Diffuse Large B-Cell Lymphoma |
| NCT06508658 | Phase 3 | Active, not recruiting | 2028-03 | Experimental | Genmab | Diffuse Large B-Cell Lymphoma |
| NCT05409066 | Phase 3 | Active, not recruiting | 2029-12 | Experimental | Genmab | Follicular Lymphoma (FL) |
| NCT06191744 | Phase 3 | Active, not recruiting | 2037-11 | Experimental | Genmab | Follicular Lymphoma (FL) |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More GMAB catalysts